NEWS

February 3, 2022
For the CEO of Travere, running a rare disease company is personal
January 27, 2022
In the News: Our president and CEO Eric Dube named Top Industry Leader by Life Sciences Voice
January 10, 2022
Travere Therapeutics Provides Corporate Update and 2022 Outlook
January 5, 2022
Landmark Study Calls for Modernization of Newborn Screening System in US
January 4, 2022
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
December 15, 2021
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
November 29, 2021
Laura Clague and Eric Dube Named to San Diego Business Journal SD 500 Most Influential People in San Diego
November 2, 2021
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
October 28, 2021
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
September 15, 2021
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
September 14, 2021
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
September 6, 2021
Travere Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis